| Dr Ishai Ross, MD | |
|
4725 N Federal Hwy Ste 504, Ft Lauderdale, FL 33308-4603 | |
| (954) 267-6780 | |
| Not Available |
| Full Name | Dr Ishai Ross |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 15 Years |
| Location | 4725 N Federal Hwy Ste 504, Ft Lauderdale, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225266232 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | ME 117833 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Trilogy Home Healthcare | Coral springs, FL | Home health agency |
| Holy Cross Hospital | Fort lauderdale, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Holy Cross Medical Group | 1850298365 | 194 |
News Archive
States across the country are making significant changes to their newborn screening programs after a Milwaukee Journal Sentinel investigation found that thousands of hospitals were sending babies' blood samples late to state labs that test for rare yet deadly genetic disorders. From keeping labs open on weekends to identifying problem hospitals and providing them with regular performance reports, dozens of health officials are reviewing and retooling their state-run programs (Gabler, 12/11).
Of the 250,000 American men who will be diagnosed with prostate cancer this year, very few of them-about 1 percent-will develop lethal, metastatic disease. Finding a way to distinguish between this small cohort and the majority of patients who will develop an indolent, non-lethal form of prostate cancer is a key goal in prostate cancer research.
Providing patients with chronic heart failure access to remote monitoring, for example by telephone or telemonitoring using wireless technology, reduces deaths and hospitalisations and may provide benefits on health care costs and quality of life. These are the conclusions of a new Cochrane Systematic Review by an international team of researchers.
Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
Kaiser Health News' Blog Watch column details some of yesterday's chatter in the blogosphere. "It was a long day of commentary for many health policy bloggers, who concluded that President Barack Obama signaled his intention to push forward with the current proposals, though who will score the most political points from the seven hour health care summit remains contentious"
› Verified 5 days ago
| Entity Name | Holy Cross Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467401877 PECOS PAC ID: 1850298365 Enrollment ID: O20031215000087 |
News Archive
States across the country are making significant changes to their newborn screening programs after a Milwaukee Journal Sentinel investigation found that thousands of hospitals were sending babies' blood samples late to state labs that test for rare yet deadly genetic disorders. From keeping labs open on weekends to identifying problem hospitals and providing them with regular performance reports, dozens of health officials are reviewing and retooling their state-run programs (Gabler, 12/11).
Of the 250,000 American men who will be diagnosed with prostate cancer this year, very few of them-about 1 percent-will develop lethal, metastatic disease. Finding a way to distinguish between this small cohort and the majority of patients who will develop an indolent, non-lethal form of prostate cancer is a key goal in prostate cancer research.
Providing patients with chronic heart failure access to remote monitoring, for example by telephone or telemonitoring using wireless technology, reduces deaths and hospitalisations and may provide benefits on health care costs and quality of life. These are the conclusions of a new Cochrane Systematic Review by an international team of researchers.
Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
Kaiser Health News' Blog Watch column details some of yesterday's chatter in the blogosphere. "It was a long day of commentary for many health policy bloggers, who concluded that President Barack Obama signaled his intention to push forward with the current proposals, though who will score the most political points from the seven hour health care summit remains contentious"
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ishai Ross, MD 4725 N Federal Hwy Ste 504, Fort Lauderdale, FL 33308-4603 Ph: () - | Dr Ishai Ross, MD 4725 N Federal Hwy Ste 504, Ft Lauderdale, FL 33308-4603 Ph: (954) 267-6780 |
News Archive
States across the country are making significant changes to their newborn screening programs after a Milwaukee Journal Sentinel investigation found that thousands of hospitals were sending babies' blood samples late to state labs that test for rare yet deadly genetic disorders. From keeping labs open on weekends to identifying problem hospitals and providing them with regular performance reports, dozens of health officials are reviewing and retooling their state-run programs (Gabler, 12/11).
Of the 250,000 American men who will be diagnosed with prostate cancer this year, very few of them-about 1 percent-will develop lethal, metastatic disease. Finding a way to distinguish between this small cohort and the majority of patients who will develop an indolent, non-lethal form of prostate cancer is a key goal in prostate cancer research.
Providing patients with chronic heart failure access to remote monitoring, for example by telephone or telemonitoring using wireless technology, reduces deaths and hospitalisations and may provide benefits on health care costs and quality of life. These are the conclusions of a new Cochrane Systematic Review by an international team of researchers.
Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
Kaiser Health News' Blog Watch column details some of yesterday's chatter in the blogosphere. "It was a long day of commentary for many health policy bloggers, who concluded that President Barack Obama signaled his intention to push forward with the current proposals, though who will score the most political points from the seven hour health care summit remains contentious"
› Verified 5 days ago
Roger Harris Shelling, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 5601 N Dixie Highway, Suite 317, Ft Lauderdale, FL 33334 Phone: 954-772-8207 Fax: 954-938-8056 | |
Paul E Tocci, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 4800 Ne 20th Ter, Ste. 404, Ft Lauderdale, FL 33308 Phone: 954-491-4950 Fax: 954-776-4437 | |
James J Garner, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 4800 Ne 20th Ter, Suite 207, Ft Lauderdale, FL 33308 Phone: 954-229-9560 Fax: 954-229-9564 |